GlassScriptPhysician profile
Fadee Michael Bittar
NPI 1508941709
$2,133.41
in general payments reported to CMS, 2019-2025
16 companies · $538 in 2025
The $538 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $43.44 · 2021: $48.53 · 2022: $446 · 2023: $374 · 2024: $232 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127 · Entertainment: $17.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.71 |
| Entertainment | $17.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $426.65 | 2019-2025 | Myday Contact Lens, Biofinity Contact Lens |
| Bausch & Lomb Americas INC. | $378.36 | 2022-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $258.53 | 2019-2025 | Precision7, Total30, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $197.43 | 2019-2020 | |
| Johnson & Johnson Vision Care, INC. | $180.13 | 2022-2025 | Acuvue |
| New World Medical,INC. | $131.20 | 2023 | |
| Abbvie INC. | $123.88 | 2025 | |
| Allergan, INC. | $112.79 | 2022 | |
| Sun Pharmaceutical Industries INC. | $111.23 | 2022-2023 | Cequa |
| Oyster Point Pharma, INC. | $91.11 | 2022-2025 | Tyrvaya |
| Horizon Therapeutics Plc | $35.21 | 2022-2023 | Tepezza |
| Harrow Eye, LLC | $19.78 | 2025 | Vevye |
| Biotissue Holdings INC. | $18.81 | 2022 | |
| Optos, INC. | $17.82 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Lkc Technologies, INC. | $16.47 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $14.01 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadee Bittar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.